TECH Stock Price Today (October 2026) — Bio-Techne Corporation Analysis & Key Metrics 2026-10-07
Bio-Techne Corporation (TECH) is trading at $72.53, up 0.14% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $70.50 (2.8% downside).
- Volatility is low (1.79% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (1.30% YoY) alongside competitive pressures in the Biotechnology space.
TECH Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Bio-Techne Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $11.40B
P/E Ratio
Forward P/E: 31.23
Revenue Growth
Year over Year
Analyst Target
-2.8% downside from target
Key Investor Questions About TECH
What investors need to know before buying
Based on current market data, TECH presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 56.14)
- Fundamentals say: Mixed signals (nuanced financial profile)
TECH's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for TECH investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $289.09M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, TECH stock traded between $43.20 and $72.69 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 1.79% annualized volatility and β=1.03, the stock exhibits moderate correlation to market moves—making TECH suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]
Is Bio-Techne Stock Outperforming the Nasdaq?
Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.
3 Reasons to Sell TECH and 1 Stock to Buy Instead
Bio-Techne has had an impressive run over the past six months as its shares have beaten the S&P 500 by 21.5%. The stock now trades at $72.56, marking a 39.5% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the past month roughly flat and the past 3 months showing a strong double digit gain. Recent trading tells a mixed story for Bio-Techne. The share price return of 29% over the past 90 days sits alongside a 1-year total shareholder return of 41%, while the 5-year total shareholder return shows a decline of 44%. This hints that momentum has only recently improved following a...
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.
1 Surging Stock for Long-Term Investors and 2 That Underwhelm
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
1 Profitable Stock to Own for Decades and 2 We Turn Down
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.
3 High-Flying Stocks We Approach with Caution
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Explore More Analysis for TECH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 3, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Bio-Techne Corporation
Bio-Techne Corporation (TECH) is currently trading at $72.53. The RSI (14-day) is at 56.1, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $70.50 implies 2.8% downside from current levels. Volatility is low at 1.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bio-Techne Corporation (TECH): The trailing P/E ratio is 62.30, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 31.23, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.97, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 5.35. Price-to-Sales is 9.33. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 10 analysts covering TECH, the consensus price target is $70.50. This represents a 2.8% downside from the current price of $72.53. The range spans from a low target of $50.00 to a high target of $73.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bio-Techne Corporation (TECH) pays a dividend with a current yield of approximately 0.44%. The annualized dividend rate is $0.32 per share. The payout ratio is 27.6%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 24, 2026.
Key risks for Bio-Techne Corporation (TECH) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bio-Techne Corporation's (TECH) current debt and financial health profile: Total debt stands at $289.09M. The debt-to-equity ratio is 0.14x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 4.55, indicating strong short-term liquidity. The quick ratio is 2.95. The company holds $265.48M in cash and equivalents. Free cash flow is positive at $229.65M, providing a cushion for debt servicing and shareholder returns.